KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $72.7 million.

  • West Pharmaceutical Services' Shares Outstanding (Diluted Average) fell 135.69% to $72.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $72.7 million, marking a year-over-year decrease of 135.69%. This contributed to the annual value of $72.7 million for FY2025, which is 135.69% down from last year.
  • West Pharmaceutical Services' Shares Outstanding (Diluted Average) amounted to $72.7 million in Q4 2025, which was down 135.69% from $72.7 million recorded in Q3 2025.
  • In the past 5 years, West Pharmaceutical Services' Shares Outstanding (Diluted Average) ranged from a high of $76.3 million in Q4 2021 and a low of $72.7 million during Q3 2025
  • Its 5-year average for Shares Outstanding (Diluted Average) is $74.8 million, with a median of $75.5 million in 2023.
  • As far as peak fluctuations go, West Pharmaceutical Services' Shares Outstanding (Diluted Average) soared by 65.96% in 2021, and later plummeted by 225.17% in 2024.
  • Quarter analysis of 5 years shows West Pharmaceutical Services' Shares Outstanding (Diluted Average) stood at $76.3 million in 2021, then decreased by 0.66% to $75.8 million in 2022, then fell by 0.66% to $75.3 million in 2023, then dropped by 2.12% to $73.7 million in 2024, then fell by 1.36% to $72.7 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $72.7 million for Q4 2025, versus $72.7 million for Q3 2025 and $72.8 million for Q2 2025.